İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

h.a.c. pharma - metildopa (levogira) - metildopa (levogira)

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - methyldopum anhydricum - compresse rivestite con film - methyldopum anhydricum 250 mg ut methyldopum 283 mg, cellulosi pulvis, acidum citricum, ethylcellulosum, guari gummi, magnesii stearas, silica colloidalis anhydrica, natrii calcii edetas corresp. natrium 0.025 mg, Überzug: acidum citricum monohydricum, hypromellosum, propylenglycolum, talcum, cera carnauba, e 104, e 171, e 172 (rubrum), pro compresso obducto. - hypertonie - synthetika

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

bayer s.p.a. - metildopa - metildopa

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

malesci istituto farmacobiologico s.p.a. - metildopa (levogira) - metildopa (levogira)

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

recordati industria chimica e farmaceutica s.p.a. - metildopa (levogira) - metildopa (levogira)

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - infezioni da hiv - antivirali per uso sistemico - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenti antineoplastici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

jntl consumer health ii (switzerland) gmbh - levocabastinum - augentropfensuspension - levocabastinum 0.5 mg ut levocabastini hydrochloridum, propylenglycolum, dinatrii phosphas et natrii dihydrogenophosphas monohydricus corresp. phosphas 9.5 mg, benzalkonii chloridum 0.15 mg, hypromellosum, polysorbatum 80, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - congiuntivite allergica - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

sintetica sa - aqua ad iniectabile - soluzione iniettabile - aqua ad iniectabile q.s. pro 1 ml. - soluzione vectrice - synthetika

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

grunenthal italia s.r.l. - levocabastina - levocabastina